OBJECTIVE: To conduct a clinical trial of intratympanic steroid injection for idiopathic sudden sensorineural hearing loss in subjects who failed oral steroid therapy. STUDY DESIGN AND SETTING: Open-label methylprednisolone injection clinical trial in a tertiary neurotologic referral center. Twenty subjects (14 males; 6 females) received 4 injections within a 2-week period (4 days apart). Hearing, dizziness, and tinnitus were evaluated before and after treatment. RESULTS: There were no serious unexpected adverse events and 2 types of expected adverse events (tympanic membrane perforation, nausea after injection). No increases in dizziness or tinnitus lasting longer than 24 hours were observed after injections. One of 20 (5%) improved to near-normal hearing. In addition, there was statistically significant improvement in 4-frequency pure-tone average and speech discrimination score at 1 month after treatment. CONCLUSION: Four intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids. SIGNIFICANCE: A clinical trial of intratympanic injections for idiopathic sudden hearing loss was successfully completed and promising results were found.
OBJECTIVE: To conduct a clinical trial of intratympanic steroid injection for idiopathic sudden sensorineural hearing loss in subjects who failed oral steroid therapy. STUDY DESIGN AND SETTING: Open-label methylprednisolone injection clinical trial in a tertiary neurotologic referral center. Twenty subjects (14 males; 6 females) received 4 injections within a 2-week period (4 days apart). Hearing, dizziness, and tinnitus were evaluated before and after treatment. RESULTS: There were no serious unexpected adverse events and 2 types of expected adverse events (tympanic membrane perforation, nausea after injection). No increases in dizziness or tinnitus lasting longer than 24 hours were observed after injections. One of 20 (5%) improved to near-normal hearing. In addition, there was statistically significant improvement in 4-frequency pure-tone average and speech discrimination score at 1 month after treatment. CONCLUSION: Four intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids. SIGNIFICANCE: A clinical trial of intratympanic injections for idiopathic sudden hearing loss was successfully completed and promising results were found.
Authors: Young Ho Kim; Kyung Tae Park; Byung Yoon Choi; Min Hyun Park; Jun Ho Lee; Seung-Ha Oh; Sun O Chang Journal: Eur Arch Otorhinolaryngol Date: 2011-12-08 Impact factor: 2.503
Authors: Petros V Vlastarakos; George Papacharalampous; Paul Maragoudakis; George Kampessis; Nicholas Maroudias; Dimitrios Candiloros; Thomas P Nikolopoulos Journal: Eur Arch Otorhinolaryngol Date: 2011-08-19 Impact factor: 2.503
Authors: Andrew A McCall; Erin E Leary Swan; Jeffrey T Borenstein; William F Sewell; Sharon G Kujawa; Michael J McKenna Journal: Ear Hear Date: 2010-04 Impact factor: 3.570
Authors: Hasan Yasan; Mustafa Tüz; Murat Yariktaş; Giray Aynali; Onder Tomruk; Omer Akkuş Journal: Indian J Otolaryngol Head Neck Surg Date: 2012-01-15